

**Louisiana Medicaid
Point-of-Sale (POS) Requirements for
Selected Enzyme Replacement Therapy Agents**

Diagnosis Code Requirement

Diagnosis Code Requirements for Selected ERT Agents	
Medication	Diagnosis Code
Brineura™ (cerliponase alfa)	E75.4 Neuronal ceroid lipofuscinosis
Cerdelga® (eliglustat tartrate)	E75.22 Gaucher disease
Cerezyme® (imiglucerase)	E75.22 Gaucher disease
Elelyso® (taliglucerase alfa)	E75.22 Gaucher disease
Galafold™ (migalastat HCL)	E75.21 Fabry (-Anderson) disease
Strensiq® (asfotase alfa)	E83.39 Other disorders of phosphorus metabolism [perinatal/infantile- and juvenile-onset hypophosphatasia]
Vpriv® (velaglucerase alfa)	E75.22 Gaucher disease
Zavesca® (miglustat)	E75.22 Gaucher disease

Fabrazyme® and Galafold™ Therapeutic Duplication POS Edit

These agents are monitored at the pharmacy POS for duplication of therapy with each other.

References

Brineura (cerliponase alfa) [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; March 2020. <https://www.brineura.com/wp-content/themes/jupiter-child/assets/pdfs/resources/Brineura-Prescribing-Information.pdf>

Cerdelga (eliglustat) [package insert]. Waterford, Ireland: Genzyme Corporation; August 2018. <http://products.sanofi.us/Cerdelga/Cerdelga.pdf>

Cerezyme (imiglucerase) [package insert]. Cambridge, MA: Genzyme Corporation; April 2018. <http://products.sanofi.us/Cerezyme/cerezyme.pdf>

Elelyso (taliglucerase alfa) [package insert]. New York, NY: Pfizer Labs; October 2019. <http://labeling.pfizer.com/ShowLabeling.aspx?id=798>

Galafold (migalastat) [package insert]. Cranbury, NJ: Amicus Therapeutics U.S., Inc; March 2020. <https://www.amicusrx.com/pi/galafold.pdf>

Strensiq (asfotase alfa) [package insert]. Boston, MA: Alexion Pharmaceuticals Inc; June 2020.
https://alexion.com/documents/strensiq_uspi

Vpriv (velaglucerase alfa) [package insert]. Lexington, MA: Shire Human Genetic Therapies Inc; November 2019. http://pi.shirecontent.com/PI/PDFs/Vpriv_USA_ENG.pdf

Zavesca (miglustat) [package insert]. San Francisco, CA: Actelion Pharmaceuticals Inc; November 2017. <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/ZAVESCA-pi.pdf>

Revision	Date
Policy created	October 2020